These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28306482)

  • 1. Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Leuk Lymphoma; 2017 Nov; 58(11):2731-2733. PubMed ID: 28306482
    [No Abstract]   [Full Text] [Related]  

  • 2. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients.
    Luo X; Li T; Hu L; Liu S; Zhao H; Zhang J; Feng Y; Huang L
    J Chemother; 2021 Apr; 33(2):95-105. PubMed ID: 32441568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation.
    Yan SQ; Seyboth B; Kobos R; Eaton A; Seo SK; Cohen N
    J Pediatric Infect Dis Soc; 2018 May; 7(2):169-171. PubMed ID: 28407118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
    Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
    J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
    Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
    Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Brown J; Freeman BB
    Bone Marrow Transplant; 2005 Jul; 36(2):177. PubMed ID: 15908975
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole.
    Barajas MR; McCullough KB; Merten JA; Dierkhising RA; Bartoo GT; Hashmi SK; Hogan WJ; Litzow MR; Patnaik MM; Wilson JW; Wolf RC; Wermers RA
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):579-83. PubMed ID: 26524731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
    Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
    Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
    Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
    Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
    Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
    Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.
    Ceberio I; Dai K; Devlin SM; Barker JN; Castro-Malaspina H; Goldberg JD; Giralt S; Adel NG; Perales MA
    Bone Marrow Transplant; 2015 Mar; 50(3):438-43. PubMed ID: 25599164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.
    Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM
    Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-independent confusion induced by voriconazole in a patient with Asian ancestry after allogeneic hematopoietic stem cell transplant.
    Hui J
    J Oncol Pharm Pract; 2016 Feb; 22(1):175-8. PubMed ID: 25178697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.
    Lecefel C; Eloy P; Chauvin B; Wyplosz B; Amilien V; Massias L; Taburet AM; Francois H; Furlan V
    J Clin Pharm Ther; 2015 Feb; 40(1):119-20. PubMed ID: 25417855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of voriconazole in hospitalised patients.
    Veringa A; Geling S; Span LF; Vermeulen KM; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JC
    Int J Antimicrob Agents; 2017 Feb; 49(2):243-246. PubMed ID: 28012684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.